This industry report describes advances in computational models and predictive assays, early elimination of high-risk compounds, clinical time and cost reduction. Plus, pharmacogenomic profiling to design safe, efficient clinical trials and a special FDA perspective on the roll of predictive metabolism in the drug approval process is included.